Navigation Links
Mevion Medical Systems Delivers the World's First Superconducting Synchrocyclotron for Proton Therapy to Barnes Jewish Hospital
Date:10/31/2011

LITTLETON, Mass., Oct. 31, 2011 /PRNewswire/ -- Mevion Medical Systems announced today it has delivered the world's first superconducting synchrocyclotron to the S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine in St. Louis MO. This inaugural shipment marks the last phase of the manufacturing of the first MEVION S250 proton accelerator module and the first of many to come deliveries of this revolutionary cancer therapy device.  

The synchrocyclotron was delivered after a 1,200 mile, 4-day trip from Mevion's Headquarters in Littleton MA to St. Louis MO.  "It was a very rewarding day to see our first system leave our factory knowing that what we have achieved may affect and improve the lives of cancer patients," stated Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. "The innovative design of the MEVION S250 makes adding proton therapy remarkably easier for our hospital partners than what was previously available."

Powered by a TriNiobium Core™, the high-energy proton source of the MEVION S250 will preserve all of the treatment benefits of conventional proton treatment systems while removing the obstacles of size, cost and complexity that have limited the wide adoption of this promising cancer treatment modality. The MEVION S250 Proton Therapy System combines a patented, gantry-mounted proton source with a highly integrated, image-based workflow and robotic patient positioning, making proton therapy a practical clinical reality.

Similar to traditional radiation therapy systems in terms of footprint, workflow, and throughput, the MEVION S250 will easily integrate within existing radiation therapy departments to deliver innovative cancer care in a very conventional way.  "Barnes Jewish Hospital prides itself in providing the most advanced technologies to its patients. We are delighted to add this latest develop
'/>"/>

SOURCE Mevion Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...
(Date:5/17/2013)... -- Medical devices are any medical items that are ... of their different mechanisms, actions and regulatory requirements, medical ... drug trails due to their unique clinical practices. Currently, ... both safety and efficacy (which is left to the ... as the SFDA) evaluate MDs for both safety and ...
(Date:5/17/2013)... 17, 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; ... Technology Small Business Technology Transfer Research (STTR) grant ... Infectious Diseases (NIAID), a division of the National ... novel human antibody therapeutics to combat Staphylococcus ... infections, including methicillin-resistant S. aureus (MRSA), ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4
... DALLAS , March 22 Texas Instruments Incorporated ... in a family of fully integrated analog front ends (AFEs) ... (EEG) equipment, as well as patient monitoring and consumer medical ... and power consumption by up to 95 percent as compared ...
... , March 22 Galderma Laboratories, L.P. today announced the U.S. Food and Drug Administration (FDA) approval of Differin® (adapalene) Lotion, 0.1%, ... April 2010 . , ... , ... ...
Cached Medicine Technology:Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 2Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 3Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 4Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 5Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 6Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 7Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 2Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 3Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 4Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 5Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 6Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 7
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... New York, New York (PRWEB) May 19, 2013 ... move forward in a federal litigation now underway in ... to a Case Management Order dated May 3rd, the ... the Bellwether Nominee Pool to eight cases rather than ... litigation is scheduled for Thursday, May 23rd. (In re: ...
(Date:5/19/2013)... Park City, Utah (PRWEB) May 19, 2013 ... new information on small business health insurance ... alternatives to traditional employer sponsored health benefits, is ... contribution and health reimbursement arrangements . ... businesses, start-ups, and the self-employed intrinsically know the ...
(Date:5/19/2013)... According to a new market research ... – 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), ... Contact IS, Infrared, X-Ray) And Geography" published by ... $8.00 billion in 2012 and is expected to ... CAGR of 3.84% from 2013 to 2018. In ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 These ... for US, UK, Spain, Japan, Italy, Germany and ... the molecular diagnostics laboratory practice, as well as ... with significant market impact during the next five ... probe and biochip technologies, test formats, detection methodologies, ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
... to the British throne has extended his generosity and assistance ... dire need of measures to get back the lost splendour. ... Clarence House, his London residence, to launch an international campaign ... a chain of palaces and temples built by Nepal's Malla ...
... a B.C. youngster a bowel, liver, pancreas and stomach. Lori MacIver ... of her son. She said, "They were telling me to prepare ... ,Her son Gairett, 18, is now recovering following a high-risk, ... now has a new bowel, stomach, liver and pancreas, all from ...
... of American families has revealed that only half of drug- ... doing so often gives positive results to 82% of them. ... Gallup poll, the USA Today/HBO Family Drug Addiction poll revealed ... addicted to drugs or alcohol. ,The findings of the ...
... milestone in the mapping of the bovine genome, which will ... disease// control in cattle. This research is slated to benefit ... up on a sequence of 2.9 million DNA base pairs, ... in one pair, which can alter the productivity of the ...
... technique for pain relief has been developed at the ... a lot of promise// in alleviating extreme pain, during ... Neurolytic block, which is a concoction of anaesthetic and ... into the para vertebral space. This works by blocking ...
... virus has afflicted 487 children and has claimed the ... the state.,The disease has been recently named// as Acute ... family welfare ministry. ,Experts at the Sanjay ... of professor in Microbiology department, Dr TN Dhole, had ...
Cached Medicine News:Health News:A Princely Assistance to the Nepal Heritage 2Health News:Rare Transplant Gives B.C Youngster 4 New Organs 2Health News:Rare Transplant Gives B.C Youngster 4 New Organs 3Health News:Eastern UP hit by killer virus – Coxsacki 2
... The instrument includes the ... has increased illumination for ... illumination. The Copeland retinoscope ... handle, and extended battery ...
... stereopsis from 800 to 40 ... young as 2 years of ... from left to right., ,Randot ... Book #1: 200 & 100 ...
... EasyEye is the only handheld non-contact tonometer with ... is streamlined, quiet and now, with constant ... a gentle puff of air. You can prove ... on the patient's hand before you start. ...
... 2000 Phenytoin Assay is a ... use in the quantitative analysis ... or plasma. Kits are packaged ... Roche COBAS MIRA, COBAS MIRA ...
Medicine Products: